Kubilay Karakoyun

8PUBLICATIONS
39CO-AUTHORS
Molecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Micro- and nanosystemsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 22, 2025
Expression of gamma-aminobutyric acid type A receptor subunit π and minichromosome maintenance-3 in breast cancer patients treated with neoadjuvant chemotherapy: a target molecule or a proliferation marker?

Yakup İriagac, Meltem Oznur, Eyyup Çavdar

|Oct 01, 2025
The role of peripheral T lymphocyte subsets and PD-1 expression as a biomarker for neoadjuvant treatment response in breast cancer.

Tarkan Yetişyiğit, Kubilay Karaboyun, Yakup İriağaç

|May 06, 2025
The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis.

Sedat Yıldırım, Tugba Başoğlu, Akif Doğan

|Dec 04, 2024
Nanotechnology in oncology: a mini review.

Eyyup Cavdar, Kubilay Karaboyun, Yakup Iriagac

|Jun 05, 2024
Comprehensive analysis of the prognostic role of laboratory indices in advanced lung cancer patients.

Eyyüp Cavdar, Kubilay Karaboyun, Kaan Kara

|May 10, 2023
Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?

Kubilay Karaboyun, Eyyup Cavdar, Yakup Irıagac

Pageof 2

Frequent Collaborators

7 joint publications

Eyyüp Çavdar

6 joint publications

Yakup Irıagac

5 joint publications

Erdoğan Selçuk Şeber

4 joint publications

Okan Avcı